Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil-9 Extended Schedule in High-Risk Women
NCT06681636Phase 2Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06681636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681636.